HLA-DRB1∗15:02, HLA-DRB1∗09:01, and HLA-DRB1∗12:01 are correlated with the development of cGVHD in the F-to-M cohort. (A-B) Cumulative incidence of cGVHD (A) and aGVHD (B) in the F-to-M cohort. The cumulative incidence of cGVHD at 1 year and grade 2-4 aGVHD at 100 days were 55.1% (95% CI, 47.2-62.3) vs 46.6% (95% CI, 42.5-50.5) and 34.5% (95% CI, 27.4-41.8) vs 34.7% (95% CI, 30.9-38.6) in the HLA-DRB1∗15:02–positive (red line) vs –negative groups (blue line), respectively (left). Similarly, the cumulative incidence of cGVHD and grade 2-4 aGVHD were 40.4% (95% CI, 34.0-46.7) vs 51.8% (95% CI, 47.5-56.0) and 32.2% (95% CI, 26.2-38.3) vs 35.8% (95% CI, 31.7-39.8) in the HLA-DRB1∗09:01–positive (red line) vs –negative groups (blue line), respectively (middle). The cumulative incidence of cGVHD and grade 2-4 aGVHD were 34.8% (95% CI, 21.3-48.6) vs 49.3% (95% CI, 45.6-52.9) and 37.0% (95% CI, 23.2-50.8) vs 34.5% (95% CI, 31.1-38.0) in the HLA-DRB1∗12:01–positive (red line) vs –negative groups (blue line), respectively (right).